Loading…
Strategic Analysis
This EIC Pathfinder Challenge funds proof-of-concept projects that translate decades of ageing research into tangible biopharmaceutical solutions for healthy ageing. Each proposal develops a proof of concept in one of three areas and must meet the objectives of that area: an intervention targeting a fundamental molecular or cellular process of ageing, tested in a physiologically aged vertebrate model; a biomarker-based tool built on previously identified candidates or ageing clocks and assessed in a retrospective study on longevity cohorts; or a New Approach Methodology capturing the aged status of more than one tissue type, benchmarked against an animal model of ageing. All proposals should consider biological sex and gender-specific health determinants. Precision nutrition, novel ageing clocks and wellness applications are out of scope, and biomarker discovery is explicitly excluded. After scoring, the portfolio retains no more than 5 intervention, 3 biomarker and 2 NAM projects, and a project duration of 5 years is highly recommended.
TRL 2 → 3
Grouped by area of the proof of concept (primary portfolio category) — a proposal targets one branch.
Intervention: Develop an intervention that targets a fundamental molecular or cellular process of ageing, such as the hallmarks of ageing
Intervention: Assess the generalisability of the intervention (showing that it is applicable more broadly to ageing-related traits beyond the primary indication targeted) by assessing the impact of the intervention on another distinct trait related to ageing
Intervention: Demonstrate proof of concept by carrying out an interventional study in a vertebrate animal model of ageing that is physiologically aged. Projects are also encouraged to include small-scale interventional clinical studies but must at a minimum anticipate how the intervention could be feasibly tested in a clinical setting
Intervention: Develop a plan for exploitation, which considers ethical and societal perception, economic viability and regulatory approval. At least two of these areas, considered most relevant for the intended application, must be assessed in greater depth, suitably informing the project's technology development and contributing to the portfolio activities
Biomarker-based tool: The tool should be based on previously identified potential biomarker candidates or ageing clocks. All types of biomarkers are welcome, for example digital, molecular or physiological biomarkers (such as frailty measurements), combinations of biomarkers and multimodal biomarkers; as well as biomarkers for different applications (e.g. predictive, diagnostics). Biomarker discovery is explicitly excluded
Biomarker-based tool: The tool should integrate different measurements of multiple molecular, anatomic, physiologic, biomechanical or biochemical traits, as appropriate, to comprehensively capture the ageing process (i.e. it should not exclusively measure a single parameter/hallmark of ageing)
Biomarker-based tool: The selected biomarker signature should enable a clear linkage between clinical features and the mechanisms of ageing to be shown
Biomarker-based tool: The signature should be robust to inter-individual and intra-individual variability in ageing to provide actionable, personalised insights
Biomarker-based tool: The tool should be assessed in an initial retrospective study to establish proof-of-concept. Applicants must therefore convincingly demonstrate that they have access to suitable longevity cohorts
Biomarker-based tool: The selection of the biomarkers and the development of the tool should prioritise deployment feasibility and actively incorporate feedback from potential users
NAM: The NAM should robustly capture the aged status of the system and the systemic/integrative nature of ageing (i.e. it should capture more than 1 molecular or cellular aspect of ageing, and more than 1 tissue type)
NAM: The NAM should be benchmarked against a relevant animal model of ageing
NAM: The NAM should be tested in the setting of a clearly specified use case (e.g. development of an intervention; as pre-clinical model in a regulatory setting)
All proposals should consider biological sex and gender-specific health determinants in their development, with reproductive ageing also in scope
Grouped by area of the proof of concept (primary portfolio category) — a proposal targets one branch.
Proof-of-concepts (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an intervention
Tools to facilitate development or adoption of the interventions above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models
Tools to facilitate development or adoption of the interventions above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models
Approaches to address the shared regulatory hurdles and societal challenges linked to ageing-related interventions, thereby facilitating their adoption
Deliver biotechnology-based interventions for healthy ageing
Accelerate the implementation of personalised care in ageing based on molecular phenotyping
Provide recommendations for regulatory pathways addressing ageing as a target to inform developers, regulators, and other decision makers
Improve citizen literacy on longevity
No EU policy alignment identified for this call.
Specific requirements
Single applicant
A single legal entity may apply if it is established in a Member State or an Associated Country, unless the Challenge states otherwise. In single beneficiary projects, mid-caps and larger companies are not permitted.
Consortium of two entities
Two independent legal entities from two different Member States or Associated Countries.
Consortium of three or more entities
At least three independent legal entities, each established in a different country: at least one in a Member State, and at least two others each in different Member States or Associated Countries.
Entities eligible for funding
Entities established in a Member State (including outermost regions and linked Overseas Countries and Territories), in a country associated to Horizon Europe Pillar III, or in one of the low- and middle-income countries listed in Annex 2, section B.2 of the EIC Work Programme 2026. Other entities may participate without funding, unless their participation is considered essential.
Exclusive focus on civil applications
Projects must focus exclusively on civil applications, and must not aim at human cloning for reproductive purposes, heritable modification of the genetic heritage of human beings, or the creation of human embryos solely for research or stem cell procurement (Annex 2, B.4).
Gender equality plan
Public bodies, research organisations and higher education establishments from Member States and Associated Countries must have a gender equality plan; a self-declaration is requested at proposal stage. This does not apply to private for-profit organisations, including SMEs (Annex 2, B.8).
Protection of European communication networks
Applications with elements that concern the evolution of European communication networks (5G, post-5G and related technologies) are subject to restrictions: entities assessed as high-risk suppliers of mobile network communication equipment are not eligible (Annex 2, B.1).
EU contribution
An EU contribution of up to EUR 4 million is considered appropriate; larger amounts may be requested if duly justified. Funding rate 100%, as a lump sum.
In order to apply, your proposal must meet the general eligibility requirements (see Annex 2 of EIC Work Programme 2026) as well as specific eligibility requirements for the Challenge (please see the Topic description above).
Please check for particular elements (e.g., specific application focus or technology) in the respective Challenge chapter.
The EIC Pathfinder Challenges support collaborative or individual research and innovation from consortia or from single legal entities established in a Member State or an Associated Country (unless stated otherwise in the specific Challenge chapter). In case of a consortium your proposal must be submitted by the coordinator on behalf of the consortium. Consortia of two entities must be comprised of independent legal entities from two different Member States or Associated Countries. Consortia of three or more entities must include as beneficiaries at least three legal entities, independent from each other and each established in a different country as follows:
The legal entities may for example be universities, research organisations, SMEs, start-ups, natural persons. In the case of single beneficiary projects, mid-caps and larger companies will not be permitted.
Applications with elements that concern the evolution of European communication networks (5G, post-5G and other technologies linked to the evolution of European communication networks) will be subject to restriction for the protection of European communication networks (see Annex II – Section B1).
The standard admissibility and eligibility conditions and the eligibility of applicants from third countries are detailed in Annex 2.
Proposal page limit and layout:
Described in Part B of the Application Form available in the Submission System.
Sections 1 to 3 of the part B of your proposal, corresponding respectively to the evaluation criteria Excellence, Impact, and Quality and Efficiency of the Implementation, must consist of a maximum of 30 format A4 pages. Excess pages will be automatically made invisible, and will not be taken into consideration by the evaluators. Please also consult Annex 2 of the EIC Work Programme 2026.
Described in Annex 2 of the EIC Work Programme 2026.
Described in Annex 2 of the EIC Work Programme 2026.
Described in Annex 2 of the EIC Work Programme 2026.
Described in Section II of the EIC Work Programme 2026.
Described in Section II of the EIC Work Programme 2026 and the Online Manual.
Described in Section II of the EIC Work Programme 2026.
Please refer to the Lump Sum Model Grant Agreement (Lump Sum MGA) used for Lump Sum EIC actions under Horizon Europe.
Described in the EIC Work Programme 2026.
Frequently Asked Questions (FAQs)
Standard application form (HE EIC Pathfinder Challenges)
Standard evaluation form (HE EIC Pathfinder Challenges)
Challenge Guide: Biotechnology for Healthy Ageing
Call-specific instructions
Information on clinical studies (HE)
Guidance: "Lump sums - what do I need to know?"
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2018/1046
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Source: EIC Work Programme 2026, p. 34-38; Challenge Guide, section 3.
Each criterion is scored from 0 to 5. The Work Programme sets a threshold per criterion and no overall threshold; the weights serve the ranking.
| Criterion | Threshold | Weight | Aspects assessed |
|---|---|---|---|
| Excellence | 4/5 | 50% | Objectives and relevance to the Challenge: How clear are the project's objectives? How relevant are they in contributing to the overall goal and the specific objectives of the Challenge? Novelty: To what extent is the proposed work ambitious and goes beyond the state-of-the-art? Plausibility of the methodology: How sound is the proposed methodology, including the underlying concepts, models, assumptions, appropriate consideration of the gender dimension in research content, and the quality of open science practices? |
| Impact | 3.5/5 | 30% | Potential Impact: How credible are the pathways to achieve the expected outcomes and impacts of the Challenge? To what extent would the successful completion of the project contribute to this? Innovation potential: How realistic is the proof of principle for demonstrating the potential impact of the technology for the challenge? How adequate are the proposed measures for protection of results and any other exploitation measures to facilitate future translation of research results into innovations with positive societal, economic or environmental impact? How suitable are the proposed measures for involving and empowering key actors that have the potential to take the lead in translating research into innovations in the future? Communication and Dissemination: How suitable are the proposed measures, including communication activities, to maximise expected outcomes and impacts for raising awareness about the project results' potential to establish new markets and/or address global challenges? |
| Quality and efficiency of the implementation | 3/5 | 20% | Work plan: How coherent and effective are the work plan (work packages, tasks, deliverables, milestones, timeline, etc.) and risk mitigation measures in order to achieve the project objectives? Allocation of resources: How appropriate and effective is the allocation of resources (comprising person-months and other cost items) to work packages and consortium members? Quality of the applicant/consortium (depends if mono or multi-beneficiaries): To what extent does the applicant / do all consortium members have the necessary capacity and high quality expertise for performing the project tasks? |
All proposals that meet the thresholds are considered together. The evaluation committee maps them on the categories of the Challenge Guide and selects a portfolio that achieves the expected outcomes and impacts of the Challenge. A proposal with a higher score may not be retained, and the committee may propose minor adjustments for the consistency of the portfolio. The portfolio paragraph of section 1.1 and the self-assessment table feed this step.
Source: EIC Work Programme 2026, p. 35-37 and Annex 2 (A.2, F.1); Part B form v4.3; Evaluation form for EIC Pathfinder Challenges.
Source: EIC Work Programme 2026, p. 33-34 and Annex 2 (E.1); Part B form v4.3, tables for section 3.1; Challenge Guide, section 5.
The selected consortia will benefit from mutual learning and the exchange of expertise, and will be encouraged to collaborate on the shared challenges faced by all ageing interventions:
A steering committee supported by the Programme Manager, an in-person kick-off meeting in year 1 and annual meetings in person, and four working groups, each project nominating at least one representative per group: WG1 Scientific and technological synergies; WG2 Market deployment (IP protection, regulatory pathways, economic viability, deployment feasibility); WG3 Ethical and societal considerations; WG4 Outreach and communication.
Source: EIC Work Programme 2026, p. 43-44; Challenge Guide, sections 4.2 and 4.3.
The Work Programme advises a work package dedicated to portfolio activities with at least 10 person-months. The Challenge Guide provides a template (Annex 1): WPX Portfolio management, from month 1 to the end of the project, with a task on portfolio governance and working groups, a task on the portfolio strategic plan and common documents, and one deliverable per reporting period, Deliverable X.2.i: Report on portfolio activities (type R, dissemination level SEN). You may describe concrete activities or remain generic. Without this work package the proposal is not scored lower, but it will be requested at grant preparation, within the same maximum grant.
| Project duration (months) | Number of periods | Period durations (months) |
|---|---|---|
| 12 | 1 | 12 |
| 18 | 1 | 18 |
| 24 | 2 | 12, 12 |
| 30 | 2 | 12, 18 |
| 36 | 2 | 12, 24 |
| 42 | 3 | 12, 12, 18 |
| 48 | 3 | 12, 18, 18 |
| 60 | 4 | 12, 16, 16, 16 |
Each work package should be a substantial part of the work plan; payments follow the work packages completed within each reporting period.
To keep portfolio activities synchronised, all projects are encouraged to consider a duration of 5 years (60 months, four reporting periods).
Source: EIC Work Programme 2026, p. 34; Challenge Guide, section 4.1 and Annex 1; Part B form v4.3, section 3.1.
Source: EIC Work Programme 2026, Annex 6, section 2.
Everything the call asks for, seen from the call's point of view. Each line shows what answers it, and which partner carries it.
This matrix lists everything the call asks for: outcomes, impacts, scope, the requirements buried in the call text, and policy alignment. Sign up free and GrantForge tracks each line against the concept you build.
| Requirement | Covered by | Carried | Status |
|---|---|---|---|
| Specific objectives | |||
| SC1Intervention: Develop an intervention that targets a fundamental molecular or cellular process of ageing, such as the hallmarks of ageing | · | · | Sign up to track |
| SC2Intervention: Assess the generalisability of the intervention (showing that it is applicable more broadly to ageing-related traits beyond the primary indication targeted) by assessing the impact of the intervention on another distinct trait related to ageing | · | · | Sign up to track |
| SC3Intervention: Demonstrate proof of concept by carrying out an interventional study in a vertebrate animal model of ageing that is physiologically aged. Projects are also encouraged to include small-scale interventional clinical studies but must at a minimum anticipate how the intervention could be feasibly tested in a clinical setting | · | · | Sign up to track |
| SC4Intervention: Develop a plan for exploitation, which considers ethical and societal perception, economic viability and regulatory approval. At least two of these areas, considered most relevant for the intended application, must be assessed in greater depth, suitably informing the project's technology development and contributing to the portfolio activities | · | · | Sign up to track |
| SC5Biomarker-based tool: The tool should be based on previously identified potential biomarker candidates or ageing clocks. All types of biomarkers are welcome, for example digital, molecular or physiological biomarkers (such as frailty measurements), combinations of biomarkers and multimodal biomarkers; as well as biomarkers for different applications (e.g. predictive, diagnostics). Biomarker discovery is explicitly excluded | · | · | Sign up to track |
| SC6Biomarker-based tool: The tool should integrate different measurements of multiple molecular, anatomic, physiologic, biomechanical or biochemical traits, as appropriate, to comprehensively capture the ageing process (i.e. it should not exclusively measure a single parameter/hallmark of ageing) | · | · | Sign up to track |
| SC7Biomarker-based tool: The selected biomarker signature should enable a clear linkage between clinical features and the mechanisms of ageing to be shown | · | · | Sign up to track |
| SC8Biomarker-based tool: The signature should be robust to inter-individual and intra-individual variability in ageing to provide actionable, personalised insights | · | · | Sign up to track |
| SC9Biomarker-based tool: The tool should be assessed in an initial retrospective study to establish proof-of-concept. Applicants must therefore convincingly demonstrate that they have access to suitable longevity cohorts | · | · | Sign up to track |
| SC10Biomarker-based tool: The selection of the biomarkers and the development of the tool should prioritise deployment feasibility and actively incorporate feedback from potential users | · | · | Sign up to track |
| SC11NAM: The NAM should robustly capture the aged status of the system and the systemic/integrative nature of ageing (i.e. it should capture more than 1 molecular or cellular aspect of ageing, and more than 1 tissue type) | · | · | Sign up to track |
| SC12NAM: The NAM should be benchmarked against a relevant animal model of ageing | · | · | Sign up to track |
| SC13NAM: The NAM should be tested in the setting of a clearly specified use case (e.g. development of an intervention; as pre-clinical model in a regulatory setting) | · | · | Sign up to track |
| SC14All proposals should consider biological sex and gender-specific health determinants in their development, with reproductive ageing also in scope | · | · | Sign up to track |
| Expected outcomes | |||
| EO1Proof-of-concepts (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an intervention | · | · | Sign up to track |
| EO2Tools to facilitate development or adoption of the interventions above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models | · | · | Sign up to track |
| EO3Approaches to address the shared regulatory hurdles and societal challenges linked to ageing-related interventions, thereby facilitating their adoption | · | · | Sign up to track |
| Other requirements | |||
| REQ1Work package dedicated to portfolio activities (at least 10 person-months advised)The Work Programme advises a work package dedicated to portfolio activities with at least 10 person-months, and the Challenge Guide provides a template for it. Without it the proposal is not scored lower, but the work package is requested at grant preparation within the same maximum grant. | · | · | Sign up to track |
| Expected impacts | |||
| EI1Deliver biotechnology-based interventions for healthy ageing | · | · | Sign up to track |
| EI2Accelerate the implementation of personalised care in ageing based on molecular phenotyping | · | · | Sign up to track |
| EI3Provide recommendations for regulatory pathways addressing ageing as a target to inform developers, regulators, and other decision makers | · | · | Sign up to track |
| EI4Improve citizen literacy on longevity | · | · | Sign up to track |
| Underlying policies | |||
| No underlying policies in this call. | |||
The binding rules of this call. Items marked auto are verified by GrantForge from the call and the template. The others are yours to confirm.
LMIC entities auto-eligible
Low/middle-income country entities are automatically eligible for funding.
Single applicant
A single legal entity may apply if it is established in a Member State or an Associated Country, unless the Challenge states otherwise. In single beneficiary projects, mid-caps and larger companies are not permitted.
Consortium of two entities
Two independent legal entities from two different Member States or Associated Countries.
Consortium of three or more entities
At least three independent legal entities, each established in a different country: at least one in a Member State, and at least two others each in different Member States or Associated Countries.
Entities eligible for funding
Entities established in a Member State (including outermost regions and linked Overseas Countries and Territories), in a country associated to Horizon Europe Pillar III, or in one of the low- and middle-income countries listed in Annex 2, section B.2 of the EIC Work Programme 2026. Other entities may participate without funding, unless their participation is considered essential.
Exclusive focus on civil applications
Projects must focus exclusively on civil applications, and must not aim at human cloning for reproductive purposes, heritable modification of the genetic heritage of human beings, or the creation of human embryos solely for research or stem cell procurement (Annex 2, B.4).
Gender equality plan
Public bodies, research organisations and higher education establishments from Member States and Associated Countries must have a gender equality plan; a self-declaration is requested at proposal stage. This does not apply to private for-profit organisations, including SMEs (Annex 2, B.8).
Protection of European communication networks
Applications with elements that concern the evolution of European communication networks (5G, post-5G and related technologies) are subject to restrictions: entities assessed as high-risk suppliers of mobile network communication equipment are not eligible (Annex 2, B.1).
EU contribution
An EU contribution of up to EUR 4 million is considered appropriate; larger amounts may be requested if duly justified. Funding rate 100%, as a lump sum.
The call requires you to pick or distribute several structuring elements before submission. These are locked at proposal creation time and drive the project backbone. Read-only here.
healthy-ageing-area
Develop a proof of concept in one of the three areas of the Work Programme. The area sets the specific objectives your proposal must meet, and the evaluation committee allocates each project to one, and only one, of these categories. No more than 5 intervention, 3 biomarker and 2 NAM projects are retained.
Intervention that prevents, delays or reverts the onset of a specific age-related disease
An innovative preventative or therapeutic biotechnology-based or pharmaceutical intervention. In the self-assessment table, classify it by purpose of intervention (prevention, delay or reversion), targeted molecular or cellular process of ageing, targeted age-related disease and broader disease area, and type of validation.
Biomarker-based tool
A biomarker based tool to enable the responsible deployment of ageing-related interventions. In the self-assessment table, classify it by application area (e.g. predictive, diagnostic), type of biomarker(s), type of measurement(s), link to the molecular or cellular mechanism of ageing, actionable insight for which clinical feature or intervention, and cohort used for validation. At least one diagnostic biomarker project is preferred.
New Approach Methodology (NAM)
A New Approach Methodology that goes beyond the current state of the art to enable the future development of interventions for healthy ageing. In the self-assessment table, classify it by way to capture the aged status of the system, tissues and/or organs captured, way to benchmark, and use case foreseen to test the NAM.
5 key insights you must internalise before writing. Each is grounded in the call text and tells you what evaluators will actually look for. Share these with your consortium before drafting.
The proof of concept belongs to one of three areas, and the evaluation committee allocates each project to one category only. An intervention must address all four of its objectives, including an interventional study in a physiologically aged vertebrate model and an exploitation plan assessing at least two of ethical and societal perception, economic viability and regulatory approval in depth. A biomarker-based tool must build on existing candidates or ageing clocks and demonstrate access to suitable longevity cohorts. A NAM must capture more than one aspect of ageing and more than one tissue type, and be benchmarked against an animal model of ageing.
Source: EIC Work Programme 2026, p. 41-42
Precision nutrition, the development of novel ageing clocks and wellness applications are out of scope, and biomarker discovery is explicitly excluded for biomarker-based tools. Every proposal should consider biological sex and gender-specific health determinants, with reproductive ageing also in scope: this also serves the gender dimension in research content assessed under Excellence.
Source: EIC Work Programme 2026, p. 42-43; Part B form v4.3, section 1.3
Proposals above all three thresholds (Excellence 4, Impact 3.5, Implementation 3) enter a second step where the evaluation committee classifies each one by primary category (intervention, biomarker-based tool or NAM) and its sub-categories, with no more than 5, 3 and 2 projects retained respectively and selects a coherent portfolio. A highly ranked proposal that has no synergy or commonality with the others may not be selected, and a proposal very similar to one already retained is set aside. Fill in the self-assessment table of the Challenge Guide in section 1.1.
Source: EIC Work Programme 2026, p. 35-37; Challenge Guide, sections 3 and 4.1
The Challenge Guide highly recommends a duration of 5 years for each project, so that joint portfolio work stays synchronised with the life cycle of the projects and each project can incorporate its outcomes. The same Guide advises a portfolio work package of at least 10 person-months, which does not lower the score if absent but is requested at grant preparation within the same budget.
Source: Challenge Guide, section 4.1 and Annex 1
At the end of each reporting period, payments are made only for the work packages completed within that period. Align work package end dates with the reporting periods of the form (for example 12 and 24 months for a 36-month project, or four periods of 12, 16, 16 and 16 months for 60 months).
Source: Part B form v4.3, tables for section 3.1
Talk to the Grant Coach to build your concept. There is no set order: start wherever your project starts. The sections below mirror what the conversation produces, and your coverage tracks the progress. You can refine everything once your project workspace is created.
The branch you're building for — it shapes what the call expects of you, and what your coverage is measured against.
The call requires you to pick or distribute several structuring elements before submission. These are locked at proposal creation time and drive the project backbone. Read-only here.
healthy-ageing-area
Develop a proof of concept in one of the three areas of the Work Programme. The area sets the specific objectives your proposal must meet, and the evaluation committee allocates each project to one, and only one, of these categories. No more than 5 intervention, 3 biomarker and 2 NAM projects are retained.
Intervention that prevents, delays or reverts the onset of a specific age-related disease
An innovative preventative or therapeutic biotechnology-based or pharmaceutical intervention. In the self-assessment table, classify it by purpose of intervention (prevention, delay or reversion), targeted molecular or cellular process of ageing, targeted age-related disease and broader disease area, and type of validation.
Biomarker-based tool
A biomarker based tool to enable the responsible deployment of ageing-related interventions. In the self-assessment table, classify it by application area (e.g. predictive, diagnostic), type of biomarker(s), type of measurement(s), link to the molecular or cellular mechanism of ageing, actionable insight for which clinical feature or intervention, and cohort used for validation. At least one diagnostic biomarker project is preferred.
New Approach Methodology (NAM)
A New Approach Methodology that goes beyond the current state of the art to enable the future development of interventions for healthy ageing. In the self-assessment table, classify it by way to capture the aged status of the system, tissues and/or organs captured, way to benchmark, and use case foreseen to test the NAM.
The problems this call frames, and who they affect. Your concept and plan address them.
Biomedical researchers, translational geroscientists, and academic laboratories focused on geroscience, New Approach Methodologies (NAMs), and longevity medicine.
SMEs, drug developers, and deeptech startups pioneering novel biotherapeutics, gene/cell therapies, delivery platforms, and diagnostic biomarkers for age-related degeneration.
European Medicines Agency (EMA), National Competent Authorities, and healthcare policy makers tasked with establishing regulatory frameworks for healthspan therapeutics.
Geriatricians, primary care specialists, and public healthcare providers transitioning toward predictive, preventive, and personalised care protocols for the ageing population.
Citizens and older adults facing age-associated chronic disease burdens, benefiting from extended healthspan, improved longevity literacy, and delayed functional decline.
The long-term impacts your project should drive, and the policies they serve.
Translating biological ageing interventions into effective preventative modalities will increase functional healthspan and compress morbidity in European populations.
Deploying validated biomarker signatures allows precise biological age stratification and early therapeutic intervention before irreversible clinical manifestations occur.
Delivering policy roadmaps and qualification protocols to EU regulators will unlock defined approval pathways for healthy ageing therapeutics and novel biomarker endpoints.
Fostering cutting-edge spin-offs and SME engagement around breakthrough biotechnological platforms, attracting deeptech venture investment into EU healthcare innovation.